Maternal antibodies from mothers of children with autism alter brain growth and social behavior development in the rhesus monkey.

1] Department of Psychiatry and Behavioral Sciences, University of California, Davis, Sacramento, CA, USA [2] California National Primate Research Center, University of California, Davis, Sacramento, CA, USA [3] The MIND Institute, University of California, Davis, Sacramento, CA, USA.
Translational Psychiatry (Impact Factor: 4.36). 07/2013; 3:e278. DOI: 10.1038/tp.2013.47
Source: PubMed

ABSTRACT Antibodies directed against fetal brain proteins of 37 and 73 kDa molecular weight are found in approximately 12% of mothers who have children with autism spectrum disorder (ASD), but not in mothers of typically developing children. This finding has raised the possibility that these immunoglobulin G (IgG) class antibodies cross the placenta during pregnancy and impact brain development, leading to one form of ASD. We evaluated the pathogenic potential of these antibodies by using a nonhuman primate model. IgG was isolated from mothers of children with ASD (IgG-ASD) and of typically developing children (IgG-CON). The purified IgG was administered to two groups of female rhesus monkeys (IgG-ASD; n=8 and IgG-CON; n=8) during the first and second trimesters of pregnancy. Another control group of pregnant monkeys (n=8) was untreated. Brain and behavioral development of the offspring were assessed for 2 years. Behavioral differences were first detected when the macaque mothers responded to their IgG-ASD offspring with heightened protectiveness during early development. As they matured, IgG-ASD offspring consistently deviated from species-typical social norms by more frequently approaching familiar peers. The increased approach was not reciprocated and did not lead to sustained social interactions. Even more striking, IgG-ASD offspring displayed inappropriate approach behavior to unfamiliar peers, clearly deviating from normal macaque social behavior. Longitudinal magnetic resonance imaging analyses revealed that male IgG-ASD offspring had enlarged brain volume compared with controls. White matter volume increases appeared to be driving the brain differences in the IgG-ASD offspring and these differences were most pronounced in the frontal lobes.


Available from: Aaron Lee, Apr 30, 2014
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Abstract: Objectives: In this study, we evaluated the impact of maternal rheumatoid arthritis (RA) in Albino rats on tooth development in their offspring. Methods: 30 female rats were divided into 2 groups control group (CG), and rheumatoid non-treated group (RhG). Induction of RA was performed in (RhG) by injection of collagen II, followed by induction of pregnancy in both groups. Results: Fetuses of (RhG) showed slower rate of development both histologically and immunohistochemically at first few days followed by rapid normal growth at 10th day. Conclusion: Maternal RA, temporarily, slow down the rate of tooth development in their fetuses, then rapid catch up of normal rate of
  • [Show abstract] [Hide abstract]
    ABSTRACT: Epidemiological studies have shown a clear association between maternal infection and schizophrenia or autism in the progeny. Animal models have revealed maternal immune activation (mIA) to be a profound risk factor for neurochemical and behavioural abnormalities in the offspring. Microglial priming has been proposed as a major consequence of mIA, and represents a critical link in a causal chain that leads to the wide spectrum of neuronal dysfunctions and behavioural phenotypes observed in the juvenile, adult or aged offspring. Such diversity of phenotypic outcomes in the mIA model are mirrored by recent clinical evidence suggesting that infectious exposure during pregnancy is also associated with epilepsy and, to a lesser extent, cerebral palsy in children. Preclinical research also suggests that mIA might precipitate the development of Alzheimer and Parkinson diseases. Here, we summarize and critically review the emerging evidence that mIA is a shared environmental risk factor across CNS disorders that varies as a function of interactions between genetic and additional environmental factors. We also review ongoing clinical trials targeting immune pathways affected by mIA that may play a part in disease manifestation. In addition, future directions and outstanding questions are discussed, including potential symptomatic, disease-modifying and preventive treatment strategies.
    Nature Reviews Neurology 10/2014; 10(11). DOI:10.1038/nrneurol.2014.187 · 14.10 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Impaired blood-brain barrier function represents an important component of hypoxic-ischemic brain injury in the perinatal period. Proinflammatory cytokines could contribute to ischemia-related blood-brain barrier dysfunction. IL-6 increases vascular endothelial cell monolayer permeability in vitro. However, contributions of IL-6 to blood-brain barrier abnormalities have not been examined in the immature brain in vivo. We generated pharmacologic quantities of ovine-specific neutralizing anti-IL-6 mAbs and systemically infused mAbs into fetal sheep at 126 days of gestation after exposure to brain ischemia. Anti-IL-6 mAbs were measured by ELISA in fetal plasma, cerebral cortex, and cerebrospinal fluid, blood-brain barrier permeability was quantified using the blood-to-brain transfer constant in brain regions, and IL-6, tight junction proteins, and plasmalemma vesicle protein (PLVAP) were detected by Western immunoblot. Anti-IL-6 mAb infusions resulted in increases in mAb (P < 0.05) in plasma, brain parenchyma, and cerebrospinal fluid and decreases in brain IL-6 protein. Twenty-four hours after ischemia, anti-IL-6 mAb infusions attenuated ischemia-related increases in blood-brain barrier permeability and modulated tight junction and PLVAP protein expression in fetal brain. We conclude that inhibiting the effects of IL-6 protein with systemic infusions of neutralizing antibodies attenuates ischemia-related increases in blood-brain barrier permeability by inhibiting IL-6 and modulates tight junction proteins after ischemia.-Zhang, J., Sadowska, G. B., Chen, X., Park, Y. S., Kim, J. -E., Bodge, C. A., Cummings, E., Lim, Y. -P., Makeyev, O., Besio, W. G., Gaitanis, J., Banks, W. A., Stonestreet, B. S. Anti-IL-6 neutralizing antibody modulates blood-brain barrier function in the ovine fetus. © FASEB.
    The FASEB Journal 01/2015; 29(5). DOI:10.1096/fj.14-258822 · 5.48 Impact Factor